LIFESTAT - Living With Statins, a Cross Sectional Study
NCT ID: NCT02250677
Last Updated: 2016-09-26
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
75 participants
Study Classification
OBSERVATIONAL
Study Start Date
2014-04-30
Study Completion Date
2016-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Background Statins are cholesterol lowering drugs that are prescribed to lower the risk of cardio-vascular diseases (CVD). The use of statins has increased markedly and it is now one of the most prescribed drugs in the world. 600,000 people in Denmark are taking statins on a daily basis, 40 % of these are taking the medication without having any other risk factors for CVD than elevated blood-cholesterol i.e. they are in primary prevention.
Statins are not without side effects and studies have shown that there is an elevated risk of developing diabetes when taking statins. This has led to an increased debate about the use of statins in primary prevention. Furthermore a large meta-analysis has shown that to prevent one event of CVD, it is necessary to treat 200 people for 3-5 years. These data suggest that more conservative use of statins to prevent CVD in otherwise healthy individuals at low risk for future CVD may be warranted.
Other side effects of statins are muscle myalgia, muscle cramps and fatigue which potentially can prevent a physically active lifestyle. The biomedical background of these side effects is not fully elucidated but it has been shown that there is a link to decreasing levels of an important enzyme, Q10, which plays a role in muscle energy metabolism.
Hypothesis
The overarching research question is: why does statin treatment cause muscle pain? Does statin treatment impair (or even prohibit) physical exercise training? Furthermore we would like to answer the following questions:
a Does statin treatment impair (or even prohibit) physical exercise training?
b Does statin treatment cause:
* Decreased muscle strength?
* Skeletal muscle inflammation?
* Decreased mitochondrial respiratory function?
c Abnormal glucose homeostasis?
Statins are not without side effects and studies have shown that there is an elevated risk of developing diabetes when taking statins. This has led to an increased debate about the use of statins in primary prevention. Furthermore a large meta-analysis has shown that to prevent one event of CVD, it is necessary to treat 200 people for 3-5 years. These data suggest that more conservative use of statins to prevent CVD in otherwise healthy individuals at low risk for future CVD may be warranted.
Other side effects of statins are muscle myalgia, muscle cramps and fatigue which potentially can prevent a physically active lifestyle. The biomedical background of these side effects is not fully elucidated but it has been shown that there is a link to decreasing levels of an important enzyme, Q10, which plays a role in muscle energy metabolism.
Hypothesis
The overarching research question is: why does statin treatment cause muscle pain? Does statin treatment impair (or even prohibit) physical exercise training? Furthermore we would like to answer the following questions:
a Does statin treatment impair (or even prohibit) physical exercise training?
b Does statin treatment cause:
* Decreased muscle strength?
* Skeletal muscle inflammation?
* Decreased mitochondrial respiratory function?
c Abnormal glucose homeostasis?
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Living With Statins - The Impact of Cholesterol Lowering Drugs on Health, Lifestyle and Well-being
NCT02255682
Cardiovascular Disease
Diabetes Mellitus
COMPLETED
PHASE4
Optimizing Statin Tratment in People Living With Diabetes
NCT04320719
Diabetes
COMPLETED
Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia
NCT00404001
Hypercholesterolemia
COMPLETED
PHASE2
Effect of a Dietary Supplement on Lipid Pattern and Liver Parameters in Hypercholesterolemia
NCT04485793
Hypercholesterolemia
COMPLETED
NA
A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease
NCT04992065
Atherosclerotic Cardiovascular Disease
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background
HYPERCHOLESTEROLEMIA AND STATIN USE IN DENMARK
Simvastatin is the most commonly prescribed statin, a class of drugs that inhibit hydroxyl-methyl-glutaryl (HMG) coenzyme A reductase, and thereby blocking biosynthesis of cholesterol in the liver. Simvastatin is prescribed for individuals with elevated low-density lipoprotein cholesterol (LDL-C) and/or total cholesterol, because these clinical parameters are viewed as a risk factor for cardiovascular-disease (CVD), even in the absence of other health problems or risk factors, such as previous myocardial infarction, diabetes or hypertension.
Approximately 40% of the prescriptions for statins are issued for primary prevention of elevated cholesterol by general practitioners to patients without bodily symptoms or signs. Only the "cholesterol number" makes the risk of heart attack and stroke visible. The lack of symptoms is likely to be of importance for patients' adherence to treatment as is adverse effects. A number of factors, such as information in mass media and changes in daily life, may affect the decision to take the treatment.
TREATMENT GUIDELINES FOR HYPERCHOLESTEROLEMIA
The guidelines (10; 12) indicate preventive treatment with statins is appropriate in individuals with \>10% predicted risk of a major vascular event within 5 years, while, some, but not all opinion-leaders advocate a 5% threshold (3; 10). Nevertheless, statin therapy failed to reduce all-cause mortality in a meta-study of 65,229 patients without CVD, some of whom had diabetes (13). Similarly, a Cochrane review analysis, which included some studies in which more than 10% of the patients had history of CVD, showed only 0.5% reduction in all-cause mortality, indicating that for every 200 patients taking statins daily for 5 years, 1 death would be prevented (15). These data suggest that more conservative use of statins to prevent CVD in otherwise healthy individuals at low risk for future CVD may be warranted.
THE DOWN-SIDE
Rhabdomyolysis (skeletal muscle cell death) is an infrequent but serious side-effect of statin use, that can on rare occasion lead to acute renal failure and death (i.e., 1.5 deaths per 106 prescriptions (11)). Statin use is much more frequently associated with muscle dysfunction, including myalgia (muscle pain), cramps, and weakness. The reported incidence of myalgia varies from 1% (pharmaceutical company reports) to as high as 75% in statin-treated athletes (9; 11). Mild to severe myalgia is a strong disincentive to regular exercise, and because regular exercise is one of the critical life-style approaches to preventing CVD and reducing blood cholesterol, this is a significant down-side of statin use. Regular exercise is also effective in preventing and treating obesity and type 2 diabetes, which themselves are risk factors for CVD (18).
The mechanism behind the myalgia is not known. However, we have recently demonstrated that muscle mitochondrial function is impaired with statin treatment and the Q10 protein may play a key role in this (8). In addition, the statins also negatively affect the glucose tolerance (8), increasing the risk of type 2 diabetes.
RESEARCH QUESTIONS:
The overarching research question is: why does statin treatment cause muscle pain? We are not the only research group in the world that try to answer that question, but we are the only one that has indeed provided a mechanistic explanation, and provided a proof-of-concept (8). We will now test this in a larger patient population.
Our background in muscle and exercise physiology and in bioenergetics makes it natural to further ask:
a Does statin treatment impair (or even prohibit) physical exercise training?
b Does statin treatment cause:
* Decreased muscle strength?
* Skeletal muscle inflammation?
* Decreased mitochondrial respiratory function?
c Abnormal glucose homeostasis?
Re question b \& c: If so, can physical training counteract this effect of statin treatment?
Methodology
COHORT
Patients that fulfil defined inclusion and exclusion criteria will be recruited from pharmacies and through advertisement in newspapers in Copenhagen. The vast majority of these patients are being treated on basis of the HeartScore risk estimation system that offers direct estimation of the ten-year risk of fatal cardiovascular disease in a format suited to the constraints of clinical practice (16) (www.HeartScore.org). A staggered recruitment will be implemented.
60 patients both men and women (age: 40-70 years; BMI: 25-35 kg/m2) that are being treated with Simvastatin minimum 40 mg/day as primary prevention are recruited. No other risk factors for CVD except elevated total cholesterol and/or elevated LDL cholesterol and mild hypertension (\<145/100 mm Hg) must be present.
The test subjects will undergo three experimental days as described below:
Experimental days:
Day 1 (½ day - overnight fasting):
* Medical history; clinical examination + ECG. Measurements: Blood pressure, weight, height, W/H-ratio, thigh circumference.
* Dual Energy X-ray Absorptiometry-scan (body composition and body fat).
* FatMax test and maximal oxygen uptake test (VO2-max) or ergometer bike.
Day 2 (½ day - overnight fasting):
* Oral glucose tolerance test + score questionnaire for muscle pain/discomfort (incl. Visual Analog Scale)
* Isokinetic strength and Rate of Force Development (PowerRig and KinCom dynamometer).
* Repeated VO2-max-test
Day 3 (1 day - overnight fasting):
* Muscle biopsy, vastus lateralis (before and after clamp) and fat biopsy from the subcutaneous adipose tissue in the abdomen.
* Intravenous glucose tolerance test (IVGTT)
* Euglycemic, hyperinsulinaemic clamp.
Statistical considerations
The major end-points are all end-point which we have tested before in other clinical populations. In general, in order to detect a 10% difference in these parameters before vs. after a training program or between statin users and control, requires 20-25 subjects in each group if an alpha level of \<0.05 and risk of type 2 error is set to 10%. 20-25 subjects are necessary if the "conventional" 20% type 2 error risk is implemented. Thus, the present study has a considerable safety-margin in terms of statistical power.
HYPERCHOLESTEROLEMIA AND STATIN USE IN DENMARK
Simvastatin is the most commonly prescribed statin, a class of drugs that inhibit hydroxyl-methyl-glutaryl (HMG) coenzyme A reductase, and thereby blocking biosynthesis of cholesterol in the liver. Simvastatin is prescribed for individuals with elevated low-density lipoprotein cholesterol (LDL-C) and/or total cholesterol, because these clinical parameters are viewed as a risk factor for cardiovascular-disease (CVD), even in the absence of other health problems or risk factors, such as previous myocardial infarction, diabetes or hypertension.
Approximately 40% of the prescriptions for statins are issued for primary prevention of elevated cholesterol by general practitioners to patients without bodily symptoms or signs. Only the "cholesterol number" makes the risk of heart attack and stroke visible. The lack of symptoms is likely to be of importance for patients' adherence to treatment as is adverse effects. A number of factors, such as information in mass media and changes in daily life, may affect the decision to take the treatment.
TREATMENT GUIDELINES FOR HYPERCHOLESTEROLEMIA
The guidelines (10; 12) indicate preventive treatment with statins is appropriate in individuals with \>10% predicted risk of a major vascular event within 5 years, while, some, but not all opinion-leaders advocate a 5% threshold (3; 10). Nevertheless, statin therapy failed to reduce all-cause mortality in a meta-study of 65,229 patients without CVD, some of whom had diabetes (13). Similarly, a Cochrane review analysis, which included some studies in which more than 10% of the patients had history of CVD, showed only 0.5% reduction in all-cause mortality, indicating that for every 200 patients taking statins daily for 5 years, 1 death would be prevented (15). These data suggest that more conservative use of statins to prevent CVD in otherwise healthy individuals at low risk for future CVD may be warranted.
THE DOWN-SIDE
Rhabdomyolysis (skeletal muscle cell death) is an infrequent but serious side-effect of statin use, that can on rare occasion lead to acute renal failure and death (i.e., 1.5 deaths per 106 prescriptions (11)). Statin use is much more frequently associated with muscle dysfunction, including myalgia (muscle pain), cramps, and weakness. The reported incidence of myalgia varies from 1% (pharmaceutical company reports) to as high as 75% in statin-treated athletes (9; 11). Mild to severe myalgia is a strong disincentive to regular exercise, and because regular exercise is one of the critical life-style approaches to preventing CVD and reducing blood cholesterol, this is a significant down-side of statin use. Regular exercise is also effective in preventing and treating obesity and type 2 diabetes, which themselves are risk factors for CVD (18).
The mechanism behind the myalgia is not known. However, we have recently demonstrated that muscle mitochondrial function is impaired with statin treatment and the Q10 protein may play a key role in this (8). In addition, the statins also negatively affect the glucose tolerance (8), increasing the risk of type 2 diabetes.
RESEARCH QUESTIONS:
The overarching research question is: why does statin treatment cause muscle pain? We are not the only research group in the world that try to answer that question, but we are the only one that has indeed provided a mechanistic explanation, and provided a proof-of-concept (8). We will now test this in a larger patient population.
Our background in muscle and exercise physiology and in bioenergetics makes it natural to further ask:
a Does statin treatment impair (or even prohibit) physical exercise training?
b Does statin treatment cause:
* Decreased muscle strength?
* Skeletal muscle inflammation?
* Decreased mitochondrial respiratory function?
c Abnormal glucose homeostasis?
Re question b \& c: If so, can physical training counteract this effect of statin treatment?
Methodology
COHORT
Patients that fulfil defined inclusion and exclusion criteria will be recruited from pharmacies and through advertisement in newspapers in Copenhagen. The vast majority of these patients are being treated on basis of the HeartScore risk estimation system that offers direct estimation of the ten-year risk of fatal cardiovascular disease in a format suited to the constraints of clinical practice (16) (www.HeartScore.org). A staggered recruitment will be implemented.
60 patients both men and women (age: 40-70 years; BMI: 25-35 kg/m2) that are being treated with Simvastatin minimum 40 mg/day as primary prevention are recruited. No other risk factors for CVD except elevated total cholesterol and/or elevated LDL cholesterol and mild hypertension (\<145/100 mm Hg) must be present.
The test subjects will undergo three experimental days as described below:
Experimental days:
Day 1 (½ day - overnight fasting):
* Medical history; clinical examination + ECG. Measurements: Blood pressure, weight, height, W/H-ratio, thigh circumference.
* Dual Energy X-ray Absorptiometry-scan (body composition and body fat).
* FatMax test and maximal oxygen uptake test (VO2-max) or ergometer bike.
Day 2 (½ day - overnight fasting):
* Oral glucose tolerance test + score questionnaire for muscle pain/discomfort (incl. Visual Analog Scale)
* Isokinetic strength and Rate of Force Development (PowerRig and KinCom dynamometer).
* Repeated VO2-max-test
Day 3 (1 day - overnight fasting):
* Muscle biopsy, vastus lateralis (before and after clamp) and fat biopsy from the subcutaneous adipose tissue in the abdomen.
* Intravenous glucose tolerance test (IVGTT)
* Euglycemic, hyperinsulinaemic clamp.
Statistical considerations
The major end-points are all end-point which we have tested before in other clinical populations. In general, in order to detect a 10% difference in these parameters before vs. after a training program or between statin users and control, requires 20-25 subjects in each group if an alpha level of \<0.05 and risk of type 2 error is set to 10%. 20-25 subjects are necessary if the "conventional" 20% type 2 error risk is implemented. Thus, the present study has a considerable safety-margin in terms of statistical power.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Cardiovascular Disease
Diabetes Mellitus
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
CASE_CONTROL
Study Time Perspective
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with myalgia
Patients with myalgia as a side effect to treatment with Simvastatin (minimum 20 mg daily)
No interventions assigned to this group
Patients without myalgia
Patients treated with Simvastatin (minimum 20 mg daily) without any side effects to the treatment
No interventions assigned to this group
Control group
Patients with elevated serum cholesterol not treated with cholesterol lowering drugs
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 40-70 years
* BMI 25-35
* Taking Simvastatin minimum 40 mg daily
* BMI 25-35
* Taking Simvastatin minimum 40 mg daily
Exclusion Criteria
* Diabetes Mellitus
* Cardiovascular disease such as arrythmia, ischaemic heart disease
* Mental disorders preventing the subject to understand the project description
* Cardiovascular disease such as arrythmia, ischaemic heart disease
* Mental disorders preventing the subject to understand the project description
Minimum Eligible Age
40 Years
Maximum Eligible Age
70 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Copenhagen
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Flemming Dela
Associate Professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Flemming Dela, MD, MDSci
Role: PRINCIPAL_INVESTIGATOR
University of Copenhagen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Copenhagen
Copenhagen, , Denmark
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Denmark
References
Explore related publications, articles, or registry entries linked to this study.
Boushel R, Gnaiger E, Schjerling P, Skovbro M, Kraunsoe R, Dela F. Patients with type 2 diabetes have normal mitochondrial function in skeletal muscle. Diabetologia. 2007 Apr;50(4):790-6. doi: 10.1007/s00125-007-0594-3. Epub 2007 Feb 15.
Reference Type
BACKGROUND
Ebrahim S, Casas JP. Statins for all by the age of 50 years? Lancet. 2012 Aug 11;380(9841):545-7. doi: 10.1016/S0140-6736(12)60694-1. Epub 2012 May 17. No abstract available.
Reference Type
BACKGROUND
Larsen S, Hey-Mogensen M, Rabol R, Stride N, Helge JW, Dela F. The influence of age and aerobic fitness: effects on mitochondrial respiration in skeletal muscle. Acta Physiol (Oxf). 2012 Jul;205(3):423-32. doi: 10.1111/j.1748-1716.2012.02408.x. Epub 2012 Feb 11.
Reference Type
BACKGROUND
Larsen S, Nielsen J, Hansen CN, Nielsen LB, Wibrand F, Stride N, Schroder HD, Boushel R, Helge JW, Dela F, Hey-Mogensen M. Biomarkers of mitochondrial content in skeletal muscle of healthy young human subjects. J Physiol. 2012 Jul 15;590(14):3349-60. doi: 10.1113/jphysiol.2012.230185. Epub 2012 May 14.
Reference Type
BACKGROUND
Larsen S, Stride N, Hey-Mogensen M, Hansen CN, Andersen JL, Madsbad S, Worm D, Helge JW, Dela F. Increased mitochondrial substrate sensitivity in skeletal muscle of patients with type 2 diabetes. Diabetologia. 2011 Jun;54(6):1427-36. doi: 10.1007/s00125-011-2098-4. Epub 2011 Mar 18.
Reference Type
BACKGROUND
Larsen S, Stride N, Hey-Mogensen M, Hansen CN, Bang LE, Bundgaard H, Nielsen LB, Helge JW, Dela F. Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance. J Am Coll Cardiol. 2013 Jan 8;61(1):44-53. doi: 10.1016/j.jacc.2012.09.036.
Reference Type
BACKGROUND
Meador BM, Huey KA. Statin-associated myopathy and its exacerbation with exercise. Muscle Nerve. 2010 Oct;42(4):469-79. doi: 10.1002/mus.21817.
Reference Type
BACKGROUND
Cholesterol Treatment Trialists' (CTT) Collaborators; Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012 Aug 11;380(9841):581-90. doi: 10.1016/S0140-6736(12)60367-5. Epub 2012 May 17.
Reference Type
BACKGROUND
Parker BA, Thompson PD. Effect of statins on skeletal muscle: exercise, myopathy, and muscle outcomes. Exerc Sport Sci Rev. 2012 Oct;40(4):188-94. doi: 10.1097/JES.0b013e31826c169e.
Reference Type
BACKGROUND
Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvanne M, Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F; European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012 Jul;33(13):1635-701. doi: 10.1093/eurheartj/ehs092. Epub 2012 May 3. No abstract available.
Reference Type
BACKGROUND
Ray KK, Seshasai SR, Erqou S, Sever P, Jukema JW, Ford I, Sattar N. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med. 2010 Jun 28;170(12):1024-31. doi: 10.1001/archinternmed.2010.182.
Reference Type
BACKGROUND
Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012 Aug 11;380(9841):565-71. doi: 10.1016/S0140-6736(12)61190-8.
Reference Type
BACKGROUND
Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011 Jan 19;(1):CD004816. doi: 10.1002/14651858.CD004816.pub4.
Reference Type
BACKGROUND
Christensen IB, Blom I, Dohlmann TL, Finger F, Helge JW, Gerhart-Hines Z, Dela F, Larsen S. Effect of Simvastatin Treatment on Mitochondrial Function and Inflammatory Status of Human White Adipose Tissue. J Clin Endocrinol Metab. 2023 Sep 18;108(10):e916-e922. doi: 10.1210/clinem/dgad259.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LIFESTAT - Cross Sectional
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Effect of Vascepa on Improving Coronary Atherosclerosis in People With High Triglycerides Taking Statin Therapy
NCT02926027
COMPLETED
PHASE4
Gene-by-Stress Interactions in Intervention Studies Significance
NCT03011645
TERMINATED
PHASE1
Genetic Influences on Statin Blood Concentrations in African Americans
NCT01569867
COMPLETED
Dyslipidemia Study Investigating The Increase In "Good Cholesterol"
NCT00169559
COMPLETED
PHASE2
Study to Evaluate Efficacy and Safety of PreLipid® on Subjects With Higher Than Normal Blood Lipid Levels
NCT02187757
COMPLETED
PHASE3
Ciprofibrate and Pre-diabetes
NCT03662984
COMPLETED
PHASE3
Statin Compliance of Patients With Non-insulin-dependent Diabetes
NCT04007133
TERMINATED
A Research Study Looking at the Effect of Food Intake on How the Medicine NN0385-0434 Behaves in the Body of Healthy Participants
NCT05091073
COMPLETED
PHASE1
Effect of Lapaquistat Acetate on Blood Cholesterol Levels in Subjects With Elevated Cholesterol
NCT00143663
COMPLETED
PHASE3
A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High Levels of Fat in the Blood
NCT05979428
COMPLETED
PHASE1
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
NCT02585778
COMPLETED
PHASE3
Evaluation of Oral Alpha-Cyclodextrin for Decreasing Serum Cholesterol
NCT01131299
COMPLETED
PHASE2
Efficacy of Lapaquistat Acetate in Subjects Currently Treated With Lipid-Lowering Therapy.
NCT00251680
COMPLETED
PHASE3
Open-label Pharmacokinetic Study of Diazoxide Choline Coated vs. Uncoated Formulations
NCT00688857
COMPLETED
PHASE1
The Low HDL On Six Weeks Statin Therapy (LOW) Study
NCT00238004
UNKNOWN
PHASE4
High-Density Lipoprotein (HDL) Modulation and Endothelial Function
NCT00150722
COMPLETED
PHASE3
Cross-over Pilot Study of Blood Cholesterol Response to Dietary Saturated Fat in Patients With Autosomal Dominant Hypercholesterolemia
NCT03756779
WITHDRAWN
NA
A Observational Study to Evaluate Lipid-lowering Drug Its Effect on Parameters in Dyslipidemia of Type 2 Diabetes.
NCT02382159
COMPLETED
Lipid Lowering in Patients With Statin Intolerance
NCT00405769
COMPLETED
NA
Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia
NCT01972178
TERMINATED
PHASE2
Safety and Efficacy of Propionate for Reduction of LDL Cholesterol
NCT03590496
COMPLETED
NA
CHOlesterol Lowering and Residual Risk in Type 2 Diabetes
NCT04369664
COMPLETED
PHASE4
Study to Test GSK256073 in Patients With Dyslipidemia
NCT00903617
COMPLETED
PHASE2
Clinical Study to Evaluate Drug-drug Interaction and Safety After Co-administration of D352 and D794 in Healthy Adult Volunteers
NCT06758661
COMPLETED
PHASE1
A Clinical Trial for Evaluation of Adequate Dose and Safety of DW-3102 in Hypercholesterolemia Patients
NCT02368613
UNKNOWN
PHASE2